Creapharm Clinical Supplies SAS

Primary objective: To determine the long-term safety and tolerability of tolebrutinib in RMS and PMS subjects; Secondary objectives: To evaluate the long-term efficacy of open-label (OL) tolebrutinib in RMS and PMS subjects with respect to disability progression, relapse rate (in RMS subjects only), and MRI parameters

Primary objectives: Part A To evaluate the effect of SAR443820 compared with placebo in slowing ALS progression (measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised [ALSFRS-R]). Part B To evaluate the long-term effects of SAR443820 on function and survival. Secondary objectives: Part A To evaluate the effects of SAR443820 compared with placebo on a composite assessment of function and survival, respiratory function, muscle strength, and quality of life (QoL); to evaluate the pharmacodynamic (PD) effects of SAR443820 compared with placebo on key disease biomarkers; to evaluate the safety and tolerability of SAR443820 compared with placebo; and to evaluate the pharmacokinetics (PK) of SAR443820. Part B Evaluate the long-term effects of SAR443820 on disease progression, survival, respiratory function, and quality of life (QoL); evaluate the long-term effects of SAR443820 on key disease biomarkers; evaluate the long-term safety and tolerability of SAR443820; and evaluate the pharmacokinetics (PK) of SAR443820.

Primary objective: To evaluate the effect of venglustat on reducing neuropathic pain and abdominal pain in subjects with Fabry disease ≥16 years who were treatment-naive or had not received treatment for at least 6 months prior to screening. Secondary objectives: To evaluate the effect of venglustat on plasma lyso GL-3 levels; To evaluate the effect of venglustat on the use of rescue analgesics; To evaluate the effect of venglustat on Fabry disease symptoms; To evaluate the safety and tolerability of venglustat in subjects with Fabry disease; To evaluate the PK of venglustat in subjects with Fabry disease.